Home> Products> Inhibitors> Lercanidipine-CAS 100427-26-7
price inquiry for CAS:100427-26-7, Product:Lercanidipine
For research use only. We do not sell to patients.

Lercanidipine CAS: 100427-26-7

Category: Inhibitors
Product Name: Lercanidipine
Cat No: I000083
CAS No: 100427-26-7
Synonyms: 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Molecular Formula: C36H41N3O6
Molecular Weight: 611.73
SMILES: CC1=C(C(OC)=O)C(C2=CC([N+]([O-])=O)=CC=C2)C(C(OC(C)(CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C)C)=O)=C(C)N1
InChI: None
InChIKey: None
Solubility: 10 mM in DMSO
Target: Calcium Channel
Storage: Store at -20°C
CAS 100427-26-7,Lercanidipine
  • Description

Lercanidipine is a calcium channel blocker of the dihydropyridine class.  Lercanidipine is a calcium channel blocker of the dihydropyridine class, which works by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. Lercanidipine was effective and well-tolerated in patients with mild-to-moderate hypertension in the daily practice. The effectiveness and safety of the drug were independent of the degree of cardiovascular risk.

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References

1:Lercanidipine-induced chylous ascites: Case report and literature review. Basualdo JE, Rosado IA, Morales MI, Fernández-Ros N, Huerta A, Alegre F, Landecho MF, Lucena JF.J Clin Pharm Ther. 2017 May 9. doi: 10.1111/jcpt.12555. [Epub ahead of print] PMID: 28485829
2:Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. Cheng KH, Cheng KC, Cheng KY, Yang YH, Lee CW, Lai WT.Curr Med Res Opin. 2017 Apr 13:1-7. doi: 10.1080/03007995.2017.1307817. [Epub ahead of print] PMID: 28300435
3:Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study. Lins R, Haerden Y, de Vries C.High Blood Press Cardiovasc Prev. 2017 Mar;24(1):29-36. doi: 10.1007/s40292-016-0177-9. PMID: 28058623
4:Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence. Antza C, Stabouli S, Kotsis V.Vasc Health Risk Manag. 2016 Nov 15;12:443-451. eCollection 2016. Review. PMID: 27895487 Free PMC Article
5:Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of stroke in rats. Gupta S, Sharma U, Jagannathan NR, Gupta YK.Exp Neurol. 2017 Feb;288:25-37. doi: 10.1016/j.expneurol.2016.10.014. Epub 2016 Oct 26. PMID: 27794423
6:Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. Tsioufis K, Tsioufis C, Dimitriadis K, Mantzouranis E, Mani I, Tousoulis D.Curr Med Res Opin. 2016 Oct;32(sup2):35-41. PMID: 27779461
7:Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Robles NR, Calvo C, Sobrino J, Espinel E, Esteban R, Mateos L, Macias JF.Curr Med Res Opin. 2016 Oct;32(sup2):29-34. PMID: 27779460
8:Vascular effects of the lercanidipine/enalapril combination: clinical relevance. Parati G.Curr Med Res Opin. 2016 Oct;32(sup2):25-28. PMID: 27779459
9:Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis. Rizzoni D.Curr Med Res Opin. 2016 Oct;32(sup2):17-23. PMID: 27779458
10:Fixed-dose lercanidipine and enalapril in field practice: a meta-analysis. Rizzoni D.Curr Med Res Opin. 2016 Oct;32(sup2):13-15. PMID: 27779457

price inquiry for CAS:100427-26-7, Product:Lercanidipine